JP2018516910A5 - - Google Patents

Info

Publication number

JP2018516910A5

JP2018516910A5 JP2017560989A JP2017560989A JP2018516910A5 JP 2018516910 A5 JP2018516910 A5 JP 2018516910A5 JP 2017560989 A JP2017560989 A JP 2017560989A JP 2017560989 A JP2017560989 A JP 2017560989A JP 2018516910 A5 JP2018516910 A5 JP 2018516910A5

Authority

JP

Japan

Prior art keywords

formulation

active pharmacological

carrier

nerve

dexamethasone

Prior art date

2016-06-02

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 claims 44
• 238000009472 formulation Methods 0.000 claims 29
• 230000000144 pharmacologic effect Effects 0.000 claims 20
• 210000005036 nerve Anatomy 0.000 claims 17
• 239000004615 ingredient Substances 0.000 claims 11
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 8
• 229920002674 hyaluronan Polymers 0.000 claims 8
• 229960003160 hyaluronic acid Drugs 0.000 claims 8
• 238000001356 surgical procedure Methods 0.000 claims 8
• 229960003957 dexamethasone Drugs 0.000 claims 7
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 7
• 230000000694 effects Effects 0.000 claims 6
• 239000000126 substance Substances 0.000 claims 6
• 230000004913 activation Effects 0.000 claims 4
• PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims 4
• 230000001225 therapeutic effect Effects 0.000 claims 4
• 229960002344 dexamethasone sodium phosphate Drugs 0.000 claims 3
• 239000003814 drug Substances 0.000 claims 3
• 230000037361 pathway Effects 0.000 claims 3
• 229920002385 Sodium hyaluronate Polymers 0.000 claims 2
• 230000015556 catabolic process Effects 0.000 claims 2
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
• 238000006731 degradation reaction Methods 0.000 claims 2
• 239000011159 matrix material Substances 0.000 claims 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 2
• 229940010747 sodium hyaluronate Drugs 0.000 claims 2
• YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims 2
• 230000002459 sustained effect Effects 0.000 claims 2
• 229940124597 therapeutic agent Drugs 0.000 claims 2
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 1
• 229940030225 antihemorrhagics Drugs 0.000 claims 1
• 230000006037 cell lysis Effects 0.000 claims 1
• 230000006800 cellular catabolic process Effects 0.000 claims 1
• 230000004640 cellular pathway Effects 0.000 claims 1
• 239000003246 corticosteroid Substances 0.000 claims 1
• 229940109239 creatinine Drugs 0.000 claims 1
• 229960004833 dexamethasone phosphate Drugs 0.000 claims 1
• VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 claims 1
• 239000002874 hemostatic agent Substances 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 239000003550 marker Substances 0.000 claims 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 1
• 229960002216 methylparaben Drugs 0.000 claims 1
• 230000000324 neuroprotective effect Effects 0.000 claims 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 1
• 229960003415 propylparaben Drugs 0.000 claims 1
• 229940001607 sodium bisulfite Drugs 0.000 claims 1
• 239000001509 sodium citrate Substances 0.000 claims 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
• 229960001790 sodium citrate Drugs 0.000 claims 1
• 235000011083 sodium citrates Nutrition 0.000 claims 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims 1
• 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 claims 1
• 239000007790 solid phase Substances 0.000 claims 1
• 239000007921 spray Substances 0.000 claims 1